Barclays
ARMP icon

Barclays’s Armata Pharmaceuticals ARMP Stock Holding History

Barclays’s Portfolio ARMP Stock Details ARMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.3K Buy
2,984
+2,830
+1,838% +$26K ﹤0.01% 4589
2026
Q1 		$1.58K Buy
+154
New +$1.3K ﹤0.01% 4871
2025
Q4 		– Sell
-6
Closed -$18 – 5232
2025
Q3 		$18 Buy
+6
New +$16 ﹤0.01% 5364

Other funds holding ARMP

MAM
Madison Asset Management Madison, Wisconsin $8.39B AUM 16.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Edgewood Management
Edgewood Management Greenwich, Connecticut $9.69B AUM 6.52% 1-Year Est. Return

Barclays's ARMP Position: Q2 2026 in Review

Barclays increased its Armata Pharmaceuticals (ARMP) stake by 1,838% in Q2 2026, buying an estimated $26K and bringing the position to 2,984 shares worth $19.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4589.

Barclays first reported a position in ARMP in Q3 2025 and has held it in 3 quarters since. 53 funds tracked by Wall St. Rank hold ARMP as of Q2 2026.

  • Barclays held 2,984 shares of Armata Pharmaceuticals worth $19.3K as of Q2 2026.
  • Barclays bought 2,830 Armata Pharmaceuticals shares in Q2 2026, an estimated $26K.
  • Armata Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4589 holding.
  • Barclays first reported a position in Armata Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 53 funds tracked by Wall St. Rank held Armata Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.